lisocabtagene maraleucel
bms
['lymsm', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'liso-cel']
congress|#ash22
the primary analysis of a randomized, phase iii transform study about liso-cel vs soc with salvage chemotherapy followed by asct as 2l treatment in patients with r/r lbcl was selected as part of the new tools and technologies theme as a best of ash abstract #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm